PhaseBio Pharmaceuticals, Inc. (PHASQ)

OTCMKTS: PHASQ · Delayed Price · USD
0.0133
+0.0012 (9.50%)
Jan 27, 2023, 3:04 PM EST - Market closed
PHASQ has decreased by -99.3% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 9 stock analysts, the average 12-month stock price forecast for PHASQ stock is $1.02, which predicts an increase of 7,598.11%. The lowest target is $1.01 and the highest is $1.05. On average, analysts rate PHASQ stock as a sell.
Analyst Consensus: Sell
Target Low Average Median High
Price $1.01 $1.02 $1.02 $1.05
Change +7522.6% +7598.1% +7598.1% +7824.5%

Analyst Ratings

The average analyst rating for PHASQ stock from 9 stock analysts is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.

Recommendation Trends

Rating Dec '22Jan '23
Strong Buy 00
Buy 00
Hold 44
Sell 22
Strong Sell 33
Total 99

Financial Forecast

Revenue This Year
9.61M
from 10.83M
Decreased by -11.32%
Revenue Next Year
4.75M
from 9.61M
Decreased by -50.56%
EPS This Year
-1.23
from -2.98
EPS Next Year
-1.10
from -1.23
Year 201920202021202220232024202520262027
Revenue
2.36M320.00K10.83M9.61M4.75M25.64M---
Revenue Growth
-
-86.45%
3,284.69%
-11.32%
-50.56%
439.86%
---
EPS
-1.43-3.39-2.98-1.23-1.10-1.01---
EPS Growth
---------
No. Analysts ---555---

Revenue Forecast

Revenue 202220232024202520262027
High 9.8M 9.7M 52.3M n/a n/a n/a
Avg 9.6M 4.7M 25.6M n/a n/a n/a
Low 9.1M n/a n/a n/a n/a n/a

Revenue Growth

Revenue Growth 202220232024202520262027
High
-9.6%
0.8%
1,000.7%
- - -
Avg
-11.3%
-50.6%
439.9%
- - -
Low
-15.6%
- - - - -

EPS Forecast

EPS 20222023202420252026
High -1.13 -0.42 -0.37 -1.13 -1.22
Avg -1.23 -1.10 -1.01 -1.07 -1.17
Low -1.27 -1.70 -1.59 -1.04 -1.13

EPS Growth

EPS Growth 20222023202420252026
High - - - - -
Avg - - - - -
Low - - - - -
Sources: Price target, rating and forecast data provided by Finnhub and sourced from Wall Street analysts and other sell-side and buy-side analysts and investors. Data disclaimer.